Streetbeat News

ITRM

Iterum Therapeutics plc

https://www.iterumtx.com

Industry

Biotechnology

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Open

1.37

Mkt cap

31M

Volume

591K

High

1.42

P/E Ratio

-0.78

52-wk high

2.50

Low

1.31

Div yield

N/A

52-wk low

0.81

Iterum Therapeutics plc held its Q3 2024 earnings call, discussing financial results and company updates. Key participants included CEO Corey Fishman and CFO Judith Matthews.

Portfolio Pulse from

November 14, 2024 | 6:30 pm

Iterum Therapeutics announced its third quarter 2024 financial results and the FDA approval of ORLYNVAH TM on October 25, 2024. The company will host a conference call to discuss these updates.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

Iterum Therapeutics has notified Pfizer of its decision to defer a milestone payment related to ORLYNVAH for two years, until October 25, 2026, as per an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 9:25 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Notable gainers included Healthcare Triangle, Monte Rosa Therapeutics, and Evoke Pharma, while Sonnet BioTherapeutics and Koninklijke Philips were among the losers. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 4:30 pm

Iterum Therapeutics (NASDAQ:ITRM) received FDA approval for Orlynvah, its first approved product, for treating uncomplicated urinary tract infections in adult women. This approval marks a significant milestone for Iterum and opens opportunities for strategic partnerships.

Portfolio Pulse from Vandana Singh

October 28, 2024 | 2:19 pm

Iterum Therapeutics has received FDA approval for ORLYNVAH™, the first-ever oral penem for treating uncomplicated urinary tract infections (uUTIs). This marks the first FDA-approved product for Iterum, targeting specific bacteria in adult women with limited treatment options.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 9:03 am

The article highlights significant intraday movements in health care stocks on Friday. Iterum Therapeutics, ImmunityBio, Impact BioMedical, Nexalin Technology, 180 Life Sciences, and Petros Pharma saw notable gains, while Monopar Therapeutics, Bionomics, Catheter Precision, Tyra Biosciences, Zenas BioPharma, and NewGenIvf Group experienced declines.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 4:31 pm

Iterum Therapeutics shares have resumed trading, which could indicate a resolution of previous issues that halted trading. Investors should monitor the stock for any further developments.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 3:30 pm

Iterum Therapeutics shares are set to resume trading at 11:30 AM ET after a temporary halt.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 3:26 pm

Iterum Therapeutics shares have resumed trading, which could indicate a resolution of previous issues or new developments for the company.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 3:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.